Widely acknowledged as the global voice of thalassaemia patients, TIF needs funds to carry out its mission to advocate and support the development and implementation of control programmes for thalassaemia, including prevention and clinical management.
TIF’s funding derives from a number of sources including international and regional funds, industry, generous donors, organisations in the pursuit of their common interest in haemoglobin disorders (thalassaemia and sickle cell disease).
The overall proportion of industry-related funding for the year 2021 was 51.22% and the non-industry funding was 48.78%. The highest contribution from a single company was 8.39%, and the total industry-related funding came from 14 companies. (Last update: November 2022)
As a patient-driven organisation, TIF is committed to maintaining its independence and will make choices and take positions based solely upon patients’ needs and perspectives.Corporate & Financial Support Policy
TIF’s work may attract the attention of public and private institutions, foundations, and other bodies, as well as companies or industry representative organisations which have a particular interest in the development of drugs, medical equipment, consumables, and other medical and healthcare related products and technologies.Our Supporters